VTVT
vTv Therapeutics Inc.
NASDAQ · Healthcare · Biotechnology · US
$33.35
−0.36%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 36.8M | — | 1.0M | — | 2.0M |
| Cost of Revenue | 1.0K | — | — | — | — |
| Gross Profit | 36.8M | — | 1.0M | — | 2.0M |
| Operating Expenses | |||||
| R&D Expense | 28.7M | 17.9M | 11.5M | 13.6M | 12.4M |
| SG&A Expense | 17.4M | 14.9M | 13.7M | 11.9M | 12.2M |
| General & Admin Expense | 17.4M | 14.9M | 13.7M | 11.9M | 12.2M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 46.1M | 32.8M | 25.2M | 25.5M | 24.6M |
| Cost and Expenses | 46.1M | 32.8M | 25.2M | 25.5M | 24.6M |
| Operating Income (EBIT) | (9.3M) | (32.8M) | (24.2M) | (25.5M) | (22.5M) |
| Non-Operating | |||||
| Interest Income | 2.9M | 1.9M | 1.6M | 472.0K | 352.0K |
| Interest Expense | 6.0K | 6.0K | — | 13.0K | 15.0K |
| Net Interest Income | 2.9M | 1.9M | 1.6M | 459.0K | 337.0K |
| Other Non-Op Income/Expense | 2.8M | 1.7M | 1.6M | (464.0K) | (2.3M) |
| Non-Operating Income (excl Interest) | (2.9M) | (1.7M) | (1.6M) | 451.0K | 2.3M |
| EBT (Pre-Tax Income) | (6.4M) | (31.1M) | (22.6M) | (26.0M) | (24.9M) |
| Income Tax Expense | — | — | 100.0K | — | 200.0K |
| Bottom Line | |||||
| Net Income | (4.8M) | (27.0M) | (18.5M) | (20.3M) | (19.2M) |
| Earnings from Cont. Ops | (6.4M) | (31.1M) | (22.7M) | (26.0M) | (25.1M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (4.8M) | (27.0M) | (18.5M) | (20.3M) | (19.2M) |
| Per Share | |||||
| Basic EPS | ($0.11) | ($3.20) | ($3.20) | ($9.71) | ($9.98) |
| Diluted EPS | ($0.11) | ($3.20) | ($3.20) | ($9.71) | ($9.98) |
| Revenue Per Share | $2.97 | $0.00 | $0.18 | $0.00 | $1.05 |
| Shares | |||||
| Basic Shares Outstanding | 12.4M | 8.4M | 5.8M | 2.1M | 1.9M |
| Diluted Shares Outstanding | 12.4M | 8.4M | 5.8M | 2.1M | 1.9M |
| Profitability Metrics | |||||
| EBITDA | (6.4M) | (31.1M) | (22.5M) | (25.9M) | (24.8M) |
| D&A | 7.0K | 16.0K | 89.0K | 90.0K | 92.0K |
| EBIT | (6.4M) | (31.1M) | (22.6M) | (26.0M) | (24.9M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026